<DOC>
	<DOC>NCT00211497</DOC>
	<brief_summary>This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.</brief_summary>
	<brief_title>Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Males and females 12 years and older Presence of inflammatory and noninflammatory lesions Acne conglobata, acne fulminans, or secondary acne (chloracne, druginduced acne, etc.) Active facial cysts or any nodulocystic lesions</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>acne vulgaris</keyword>
	<keyword>acne</keyword>
	<keyword>Propionibacterium acnes</keyword>
	<keyword>topical</keyword>
	<keyword>inflammatory</keyword>
	<keyword>non-inflammatory</keyword>
	<keyword>lesion counts</keyword>
	<keyword>lesions</keyword>
</DOC>